# A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

Source: https://onco.cc/trials/nct02663908/  
OnCo record `nct02663908` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Degarelix in Prostate cancer, run by Ferring Pharmaceuticals, recorded as terminated on the registry.

## Summary

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease is a phase 3 interventional study registered as NCT02663908 by Ferring Pharmaceuticals, with 545 participants recorded, started 2016-04-19 and due to reach its primary completion in 2021-03-29. Interventions recorded: Degarelix, Leuprolide. Conditions recorded: Prostate Cancer.

Linked to the drug Degarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02663908
- Phase: 3
- Setting: A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)
- Sponsor: Ferring Pharmaceuticals
- Enrolled: 545

## Sources

- ClinicalTrials.gov NCT02663908: https://clinicaltrials.gov/study/NCT02663908

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Degarelix](https://onco.cc/drugs/degarelix/)
- companies: [Ferring Pharmaceuticals](https://onco.cc/companies/ferring/)

---
JSON: https://onco.cc/api/v1/entities/nct02663908.json